BR112012013365A2 - co-cristal do composto, método para preparar um co-cristal do composto, composição farmacêutica, uso de um co-cristal do composto, e, método de tratamento de complicações trombóticas arteriais - Google Patents
co-cristal do composto, método para preparar um co-cristal do composto, composição farmacêutica, uso de um co-cristal do composto, e, método de tratamento de complicações trombóticas arteriaisInfo
- Publication number
- BR112012013365A2 BR112012013365A2 BR112012013365A BR112012013365A BR112012013365A2 BR 112012013365 A2 BR112012013365 A2 BR 112012013365A2 BR 112012013365 A BR112012013365 A BR 112012013365A BR 112012013365 A BR112012013365 A BR 112012013365A BR 112012013365 A2 BR112012013365 A2 BR 112012013365A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- crystal
- acid
- thrombotic complications
- arterial thrombotic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
co-cristal do composto, método para preparar um co-cristal do composto, composição farmacêutica, uso de um co-cristal do composto, e, método de tratamento de complicações trombóticas arteriais. a presente invenção refere-se a novas formas de co-cristal do composto da fórmula (i); em que a mólecula co-formadora é selecionada a partir do ácido glicólico, ácido salicílico, ácido decanóico (cáprico), ácido gentísico (ácido 2,5-di-hidróxi benzóico), ácido glutárico, ácido vanílico (ácido 4-hidróxi-3-metóxi benzóico ), ácido succínico, ácido malônico ou maltol (3-hidróxi-2-metil-4-pirona); e a processos para a sua preparação, a composições farmacêuticas contendo tais co-cristais, e ao uso de tais co-cristais na manufatura de medicamento para o uso na prevenção de complicações trombóticas arteriais em pacientes com doença da artéria coronária, cerebrovascular ou vascular periférica e a métodos para o tratamento de tais doenças no corpo humano ou animal através da administração de uma quantidade terapeuticamente efetiva de um co-cristal de composto da fórmula (i).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26630709P | 2009-12-03 | 2009-12-03 | |
| PCT/GB2010/002222 WO2011067571A1 (en) | 2009-12-03 | 2010-12-03 | Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012013365A2 true BR112012013365A2 (pt) | 2016-03-01 |
Family
ID=43535876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012013365A BR112012013365A2 (pt) | 2009-12-03 | 2010-12-03 | co-cristal do composto, método para preparar um co-cristal do composto, composição farmacêutica, uso de um co-cristal do composto, e, método de tratamento de complicações trombóticas arteriais |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8883802B2 (pt) |
| EP (1) | EP2507242A1 (pt) |
| JP (1) | JP2013512886A (pt) |
| KR (1) | KR20120123659A (pt) |
| CN (2) | CN104230936A (pt) |
| AU (1) | AU2010326361A1 (pt) |
| BR (1) | BR112012013365A2 (pt) |
| CA (1) | CA2781182A1 (pt) |
| MX (1) | MX2012006375A (pt) |
| RU (1) | RU2012126029A (pt) |
| WO (1) | WO2011067571A1 (pt) |
| ZA (1) | ZA201204940B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013014035A (es) * | 2011-06-01 | 2014-01-23 | Astrazeneca Ab | Nuevo co-cristal ticagrelor. |
| WO2013150495A2 (en) | 2012-04-05 | 2013-10-10 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
| WO2013186726A2 (en) * | 2012-06-15 | 2013-12-19 | Basf Se | Multicomponent crystals comprising dasatinib and selected cocrystal formers |
| EA024825B8 (ru) * | 2012-06-29 | 2016-12-30 | Зентива, К.С. | Сокристалл тикагрелора с 3-гидрокси-2-нафтойной кислотой, способ его получения и применение |
| CA2877541C (en) | 2012-07-04 | 2020-06-30 | Lek Pharmaceuticals D.D. | Ticagrelor adducts with divalent metal salts |
| CZ2012705A3 (cs) | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
| MX2015013059A (es) * | 2013-03-15 | 2016-08-05 | Bionomics Ltd | Sales, co-cristales, y polimorfos de un compuesto ansiolitico. |
| WO2014170026A1 (en) | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Stabilized amorphous ticagrelor |
| EP2813216A1 (en) | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Stabilized amorphous ticagrelor |
| CN104341423B (zh) * | 2013-08-02 | 2017-03-01 | 上海京新生物医药有限公司 | 替格瑞洛的一水合物及其制备方法与在制药中的应用 |
| CZ2013866A3 (cs) | 2013-11-08 | 2015-05-20 | Zentiva, K.S. | Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru |
| CN103601726B (zh) * | 2013-12-02 | 2016-09-28 | 浙江大学 | 两种替格瑞洛药物共晶及其制备方法 |
| WO2015183801A1 (en) | 2014-05-27 | 2015-12-03 | R. J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| US9896429B2 (en) | 2014-05-27 | 2018-02-20 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| US10508096B2 (en) | 2014-05-27 | 2019-12-17 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| WO2016116942A1 (en) | 2015-01-20 | 2016-07-28 | Anlon Chemical Research Organization | Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin |
| CN108495563B (zh) | 2015-11-25 | 2022-04-26 | R.J.雷诺兹烟草公司 | 烟碱盐、共晶体和盐共晶体配合物 |
| CA3009610C (en) | 2015-12-24 | 2024-02-13 | Takeda Pharmaceutical Company Limited | Cocrystal of (s)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1h-1,2,4-triazol-5(4h)-one, production method thereof and pharmaceutical composition containing said cocrystal |
| US10905691B2 (en) | 2016-09-09 | 2021-02-02 | Université de Liège | Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection |
| EP3292867B1 (en) * | 2016-09-09 | 2019-05-15 | Université de Liège | Triazolo(4,5-d)pyrimidine derivatives for use in the prevention and treatment of bacterial infection |
| WO2019049049A1 (en) | 2017-09-05 | 2019-03-14 | R. J. Reynolds Tobacco Company | SALTS, CO-CRYSTALS, AND CO-CRYSTAL COMPLEXES OF NICOTINE SALTS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR017014A1 (es) | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| SE0101932D0 (sv) * | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
-
2010
- 2010-12-03 BR BR112012013365A patent/BR112012013365A2/pt not_active IP Right Cessation
- 2010-12-03 CN CN201410302272.7A patent/CN104230936A/zh active Pending
- 2010-12-03 WO PCT/GB2010/002222 patent/WO2011067571A1/en active Application Filing
- 2010-12-03 US US13/513,482 patent/US8883802B2/en not_active Expired - Fee Related
- 2010-12-03 MX MX2012006375A patent/MX2012006375A/es not_active Application Discontinuation
- 2010-12-03 AU AU2010326361A patent/AU2010326361A1/en not_active Abandoned
- 2010-12-03 JP JP2012541573A patent/JP2013512886A/ja active Pending
- 2010-12-03 KR KR1020127017184A patent/KR20120123659A/ko not_active Application Discontinuation
- 2010-12-03 CN CN2010800630504A patent/CN102770434A/zh active Pending
- 2010-12-03 EP EP10803467A patent/EP2507242A1/en not_active Withdrawn
- 2010-12-03 CA CA2781182A patent/CA2781182A1/en not_active Abandoned
- 2010-12-03 RU RU2012126029/04A patent/RU2012126029A/ru not_active Application Discontinuation
-
2012
- 2012-07-02 ZA ZA2012/04940A patent/ZA201204940B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012006375A (es) | 2013-03-21 |
| CA2781182A1 (en) | 2011-06-09 |
| CN104230936A (zh) | 2014-12-24 |
| ZA201204940B (en) | 2013-03-27 |
| CN102770434A (zh) | 2012-11-07 |
| JP2013512886A (ja) | 2013-04-18 |
| AU2010326361A1 (en) | 2012-06-07 |
| KR20120123659A (ko) | 2012-11-09 |
| US20130040970A1 (en) | 2013-02-14 |
| US8883802B2 (en) | 2014-11-11 |
| EP2507242A1 (en) | 2012-10-10 |
| WO2011067571A1 (en) | 2011-06-09 |
| RU2012126029A (ru) | 2014-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012013365A2 (pt) | co-cristal do composto, método para preparar um co-cristal do composto, composição farmacêutica, uso de um co-cristal do composto, e, método de tratamento de complicações trombóticas arteriais | |
| BR112013030547A2 (pt) | cocristal de ticagrelor | |
| CN106102737B (zh) | 色甘酸衍生物以及成像和治疗的相关方法 | |
| BR0212455A (pt) | Composto, formulação farmacêutica, combinação, uso de um composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, e, processo para preparar um composto | |
| BRPI0518398A2 (pt) | Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos | |
| BRPI0707697A2 (pt) | composiÇÕes virucidas contendo metais e usos | |
| BR112014031394A2 (pt) | composições e métodos para absorção transmucosa | |
| JP2016500092A (ja) | 皮膚炎治療 | |
| BR112012003464B8 (pt) | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica | |
| JP2022503890A (ja) | ２－（１－アシルオキシ－ｎ－ペンチル）安息香酸と塩基性アミノ酸またはアミノグアニジンによって形成される塩と、その製造方法及び用途 | |
| WO2013161994A1 (ja) | 鎮痛剤 | |
| RU2008138358A (ru) | Композиция с фиксированной дозой фитата и цинка | |
| JP2012518671A5 (pt) | ||
| TWI702952B (zh) | 異喹啉衍生物用於糖尿病傷口癒合的用途 | |
| PT2222293E (pt) | Utilização médica de hidrogenopropionato e fumarato de 3-(2,2,2- trimetil-hidrazínio) e di-hirogenofosfato | |
| RU2613189C1 (ru) | Средство, повышающее антиметастатическую активность циклофосфана | |
| MX2021008658A (es) | Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk). | |
| WO2016033802A1 (zh) | 类黄酮化合物在制备伤口愈合组合物的用途 | |
| JP6294773B2 (ja) | 口腔粘膜疾患の予防または治療用経口製剤 | |
| BR112022008265A2 (pt) | Composições farmacêuticas contendo diácido de oligossacarídeo de alginato | |
| RU2538636C1 (ru) | Средство с глютаминовой кислотой и экстрактом прополиса, обладающее ноотропной активностью | |
| RU2280458C1 (ru) | Противовоспалительная мазь | |
| JP5734134B2 (ja) | 抗疲労用医薬組成物 | |
| KR101121977B1 (ko) | 8-메톡시메틸-3-아이소부틸-1-메틸잔틴을 포함하는 이상지질혈증 관련 질환 예방 또는 치료용 조성물 | |
| RU2630576C1 (ru) | Средство, обладающее гипогликемическим, гиполипидемическим и энергопротективным влиянием |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |